Table of Contents For The Transition Period From To Commission file number: 001-40523 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ELEVATION ONCOLOGY, INC. Indicate by check mark if the registrant is not required to file reports pursuant to Section 1 ...

-- Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ) cancer -- -- Expect to report initial data from combination cohort in 4Q 2025 or 1Q 2026 ---- On-track to report additional monotherapy data from dose escalation and expansion cohorts of ongoing Phase 1 clinical trial in 1H 2025 ---- Plan to present preclinical data for HER3 ADC EO-1022 in 1H 2025 and file an ...

Core Insights - Elevation Oncology announced new preclinical data supporting the combination of EO-3021 with VEGFR2 or PD-1 inhibitors, demonstrating enhanced anti-tumor activity [1][2] - The company plans to initiate dosing in the combination portion of its ongoing Phase 1 clinical trial of EO-3021 in the fourth quarter of 2024 [1][3] Preclinical Data - EO-3021 combined with DC101 (a VEGFR2 inhibitor surrogate) showed tumor growth inhibition (TGI) of 88.2%, significantly higher than 20.1% for EO-3021 alone and 59.2% for DC101 alone [2] - The combination of EO-3021 with a PD-1 inhibitor resulted in a TGI of 79.9%, compared to 33.8% for EO-3021 alone and 25.0% for the PD-1 inhibitor alone [2] - 92% of mice treated with the EO-3021 and PD-1 inhibitor combination achieved a complete response (CR), compared to 50% for EO-3021 monotherapy and 17% for the PD-1 inhibitor alone [2] Clinical Trial Plans - The ongoing Phase 1 clinical trial will evaluate EO-3021 in combination with ramucirumab (a VEGFR2 inhibitor) in the second-line setting and with dostarlimab (a PD-1 inhibitor) in the front-line setting [3][6] - Elevation Oncology continues to enroll patients in the monotherapy dose expansion portion of the trial, with additional data expected in the first half of 2025 [3] Regulatory Designations - EO-3021 received Fast Track designation from the FDA for treating advanced or metastatic gastric/GEJ cancer expressing Claudin 18.2 [7] - The drug also holds orphan drug designation for gastric cancer since November 2020 and for pancreatic cancer since May 2021 [7] Company Overview - Elevation Oncology focuses on developing selective cancer therapies for solid tumors with significant unmet medical needs, leveraging expertise in antibody-drug conjugates (ADCs) [9] - The lead candidate, EO-3021, targets Claudin 18.2 and is currently in a Phase 1 trial for advanced gastric/GEJ adenocarcinoma [9]

BOSTON, Nov. 26, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, President and Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 8:30 a.m. ET.A live w ...

Exhibit 99.1 Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements -- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Progressed into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Expect to present preclinical data on the combination potential of EO-3021 ...

-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile ---- Progressed into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 ---- Expect to present preclinical data on the combination potential of EO-3021 with VEGFR2 or PD-1 inhibitors at ESMO Immuno-Oncology Annual Congress 2024 (ESMO-IO 2024) ---- Expect to initiate dosing ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40523 Elevation Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1771427 ...

Core Viewpoint - Elevation Oncology, Inc. (ELEV) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive shift in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which have a strong correlation with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in stock price movements [4]. Company Performance Indicators - For the fiscal year ending December 2024, Elevation Oncology is expected to earn -$0.82 per share, reflecting a 38.8% change from the previous year's reported number [8]. - Over the past three months, the Zacks Consensus Estimate for Elevation Oncology has increased by 11.3%, indicating a positive trend in earnings outlook [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a 'Strong Buy' rating, highlighting the superior earnings estimate revision feature of these stocks [10].

Overview of Empery Asset Management - Empery Asset Management, located at 1 Rockefeller Plaza, New York, focuses on investments in healthcare and consumer cyclicals, managing an equity portfolio valued at approximately $17 million [2] - The firm has a portfolio of 88 stocks, with top holdings including Unity Biotechnology Inc and Greenwave Technology Solutions Inc [2] Recent Transaction - On September 30, 2024, Empery Asset Management acquired 4,000,000 shares of Elevation Oncology Inc at a price of $0.5999 per share, increasing its stake in the company to 4.99% [1] - This acquisition represents a strategic move within the healthcare sector, enhancing the firm's exposure to biotechnology [4] Insight into Elevation Oncology Inc - Elevation Oncology Inc specializes in developing targeted therapeutics for cancer treatment, focusing on rare genomic alterations [3] - Since its IPO on June 25, 2021, Elevation Oncology has faced significant market challenges, with a current market capitalization of $31.511 million and a stock price of $0.5331, reflecting a 96.19% decline since its IPO [3][5] Financial Health and Growth Prospects - Elevation Oncology's financial health is concerning, with a Profitability Rank of 1/10 and a Growth Rank of 0/10, although its balance sheet scores better with a rank of 7/10 [6] - The company has a cash-to-debt ratio of 3.59, but negative EBITDA and earnings growth over the past three years raise concerns about its long-term growth prospects [6] Market Performance and Valuation Metrics - Elevation Oncology's stock has declined 15.25% year-to-date, with a GF Score of 33/100 indicating challenges in market performance and future potential [5] - The stock's current price-to-GF Value ratio stands at 0.00, suggesting difficulties in assessing its fair market value [5] Comparative Industry Analysis - Within the biotechnology industry, Elevation Oncology's financial and market performance metrics lag behind industry standards, raising questions about its competitive standing [7] - The firm's focus on niche genomic alterations provides a unique market position, but its financial metrics and market performance are concerning [7] Conclusion - Empery Asset Management's acquisition of Elevation Oncology shares reflects a calculated risk in a volatile sector, highlighting a long-term investment strategy that may depend on future scientific breakthroughs and market acceptance of ELEV's therapeutic developments [8]

xphotoz/iStock via Getty Images Introduction The 'Undercovered' Dozen series highlights undercovered stocks on our platform for you to have another source for idea generation. This time we're looking at ideas published between August 1st - 8th. Take a look at what these less-covered ideas might hold for you. And please join the conversation below to share what you think: are any of these worth following up on? Ticker Rating Analyst OTCPK:SFTBY, OTCPK:SFTBF Hold Wide Alpha It does not matter how many Nobel P ...